New Prescribing Behavior Research Presented by Xcenda Oncology Experts at San Antonio Breast Cancer Symposium
December 1, 2018
Xcenda is proud to present exclusive research at this year's San Antonio Breast Cancer Symposium on December 4-8, 2018. This Symposium is designed to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease, to an international audience of academic and private physicians and researchers.
Transforming Oncology Prescriber Insights into Actions
As new agents for breast cancer treatments are approved, new standards of care and new treatment patterns emerge in the oncology therapy landscape. It's important to obtain both qualitative and quantitative assessments in prescribing behavior to inform strategies for continued access to these life-changing therapies.
Xcenda's team of Oncology Insights experts examined these new agents in a research poster to be presented at the San Antonio Breast Cancer Symposium on December 4–8, 2018. Their research utilized Xcenda's premier market research tool, Challenging Cases, and found key factors determining prescribing preferences.
|Evolving Treatment Patterns in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
View poster >
|Maria Lankford; Arden Buettner; Susan Britton, RN; Joanne Willey, RN; Mitch Scharf|
*Check back here after December 7 to view a copy of the poster.
Understanding Provider Perspectives
Turn to Xcenda to understand the perspectives of health care providers. Our experts use a variety of customized primary research methodologies, including standard and proprietary approaches, revealing the “how and why” behind prescriber behavior.